Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Andres Forero‐Torres et al.|npj Breast Cancer|2021Cited by 29
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E. Lang, Laura J. Esserman, Andres Forero‐Torres et al.|npj Breast Cancer|2022Cited by 27
Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trialBeverly Kyalwazi, Laura J. Esserman, Christina Yau et al.|Cancer Research|2022Cited by 3